

Resignation of Non-Executive Director

Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), a late-stage drug development company, wishes to advise that independent Non-Executive Director Mr John Gaffney has resigned, effective immediately. After serving on the Paradigm Board for over 9 years, John is now looking to focus on his other roles.

Non-Executive Director Amos Meltzer will assume the role of Chair of the Company’s Remuneration and Nomination Committee.

The Board takes this opportunity to thank John for his many years of service as a Director and wishes him the best in the future.

The Board understands the importance of maintaining a Board with a majority of Independent Directors and has already commenced a search for a suitable addition to the Paradigm Board.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Authorised for release by the Company Secretary on behalf of the Board.

To learn more please visit: <https://paradigmbiopharma.com/>

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com